## CNC: Centene Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 2.5% below STRENGTH zone (4.0-10.0%); PEG 1.64 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-5.0% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($35.73)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Centene Corp. stock underperforms Monday when compared to competitors**
- Source: MSN | 20251202T150817 | Somewhat-Bearish | Relevance: 100%
- Centene Corp. stock experienced an underperformance on Monday compared to its competitors. The stock closed down while its rivals saw gains, reflecting a mixed day in the market for healthcare companies. This suggests potential volatility or specific company-related factors influencing Centene's performance relative to the broader sector.

**2. Meridian Health Plan of Illinois Commits $1.15 Million to Expand St. Louis Area Foodbank Mobile Pantry Program**
- Source: ADVFN | 20251202T173900 | Somewhat-Bullish | Relevance: 100%
- Meridian Health Plan of Illinois is providing a $1.15 million grant over three years to the St. Louis Area Foodbank's "Food On The Move" mobile pantry program. This initiative, aligned with Meridian's "Eat Well, Be Well" program, aims to combat food insecurity and provide healthy food and nutrition education to underserved populations, food deserts, and rural areas across Illinois. The grant will support over 300 mobile market distributions, anticipating serving 60,000 community members through 2028, and will integrate health screenings and vaccinations starting in 2026.

**3. Q3 Earnings Review: Health Insurance Providers Stocks Led by CVS Health (NYSE:CVS)**
- Source: Finviz | 20251203T223600 | Bullish | Relevance: 75%
- The Q3 earnings season review for health insurance providers shows strong revenue beats but a collective decline in share prices, down 2.4% on average. CVS Health, despite strong revenue and CEO commentary on improved operations, saw an 8.3% stock decline, while Centene's exceptional quarter led to a 17.3% stock increase. Molina Healthcare and Oscar Health reported weaker results, with Oscar Health missing revenue expectations and UnitedHealth showing mixed results with flat customer numbers.

**4. Why Myriad Genetics (MYGN) Stock Is Trading Lower Today**
- Source: Finviz | 20251201T123600 | Somewhat-Bullish | Relevance: 68%
- Shares of Myriad Genetics (NASDAQ:MYGN) fell 6% after the FDA approved a competing blood-based prostate cancer test from Cleveland Diagnostics, IsoPSA. This new diagnostic kit increases competition in the prostate cancer market, raising investor concerns about Myriad's market share. Investors reacted negatively to the news, signaling increased competition in cancer diagnostics.

**5. Quadrant Capital Group LLC Cuts Stock Position in Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20251202T020915 | Somewhat-Bearish | Relevance: 63%
- Quadrant Capital Group LLC reduced its stake in Elevance Health, Inc. by 25.5% in the second quarter, selling 948 shares to hold 2,769 shares valued at $1.08 million. Despite this reduction by one firm, other large institutional investors like Vanguard, Sanders Capital, Nuveen, Orbis Allan Gray, and Boston Partners increased their positions in the company, with institutional ownership reaching 89.24%. Elevance Health also reported strong Q3 earnings, beating analyst expectations for both EPS and revenue, and declared a quarterly dividend of $1.71.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 3, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | Bernstein | $45 | $36 | +25% |
| 2025-11-12 | Wells Fargo | $35 | $41 | -15% |
| 2025-11-04 | JP Morgan | $38 | $30 | +27% |
| 2025-11-04 | Barclays | $44 | $35 | +26% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | Bernstein | main | Outperform |
| 2025-11-12 | Wells Fargo | main | Equal-Weight |
| 2025-11-04 | JP Morgan | main | Neutral |
| 2025-11-04 | Barclays | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($0.00M) |
| Sells | 2 ($2.58M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.6% (-2.8%)
- Blackrock Inc.: 9.2% (+0.3%)
- State Street Corpora: 4.3% (-7.7%)
- AQR Capital Manageme: 3.0% (+76.6%)
- Geode Capital Manage: 2.6% (-4.8%)

### Key Risks

1. Long-term trend broken: trading 13.0% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +26%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.64 elevated, pricing in significant growth expectations. Forward P/E 13.4x attractive for 43% earnings growth. Balance sheet: $1.1B free cash flow. Analyst sentiment positive (3 raises, avg +26%). Insider selling cluster ($2.6M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.9B |
| Beta | 0.48 |
| 52W Range | $25.08 - $66.81 |
| Short Interest | 2.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.64 |
| Forward P/E | 13.4 |
| Current P/E | 19.2 |
| YoY Growth | 43.0% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 7.5% to 2.5% (-5.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.5pp (needs >4.0% for momentum thesis). MRS_5 (-0.6%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 4.4% shows strong absolute momentum above own 20MA. Below SMA200 (0.87x), long-term trend not supportive. RSI neutral at 58. OFD pattern: +DUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.49% (CS: 74) | Neutral |
| RSI_14 | 57.9 | Neutral |
| MACD Histogram | 0.18 | Bullish |
| vs SMA20 | 1.044x | Above |
| vs SMA50 | 1.068x | Above |
| vs SMA200 | 0.870x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $38.81
- **Stop Loss:** $35.73 (7.9% risk)
- **Target:** $41.89 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 308
- **Position Value:** $11,953.48
- **Portfolio %:** 11.95%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-03 (Est: $-1.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $0.50 | +404.3% |
| 2025Q2 | $0.21 | $-0.16 | -177.3% |
| 2025Q1 | $2.52 | $2.90 | +15.3% |
| 2024Q4 | $0.49 | $0.80 | +62.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*